Dr Reddy’s recalls single lot of breast cancer drug from US
New Delhi: Pharmaceuticals major Dr Reddy’s Laboratories has recalled a single lot of Docetaxel injection vials, used for treatment of breast cancer, USFDA has said.
As per the US health regulator’s enforcement report for the week of 17 January, a single lot of 1,051 vials of Docetaxel injection USP, 20 mg/mL was distributed in the US, Uzbekistan and Myanmar.
The company has recalled the drug on account of defective container, the report said.
“Product complaints received of defect in the seal of the Docetaxel injection vials that the aluminium seal and/or stopper is removed when the cap is flipped off,” it said.
The vials were manufactured by Dr Reddy’s Laboratories at its Visakhapatnam facility, the United States Food and Drug Administration has said.
The voluntary ongoing recall is a class II recall, the regulator said. As per the USFDA, a class II recall is initiated in a situation, “in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”. Shares of the company were trading 1.23% higher at Rs 2,492.05.
- Tata Power, Actis in fray to buy Essel’s solar power plants
- At $78,000, Tesla moves mass-market Model 3 beyond masses
- Munjal-Burman may choose rights offer for Fortis over SRL Diagnostics sale
- Suzuki, Toyota may decide on tie-up by end of 2018-19
- Organized supply chain, growing crops in sync with demand can boost farmers’ incomes